CRISPR-based epigenetic editing shows promise in silencing hepatitis B genes

A new CRISPR-based technique targets the epigenome to turn off genes that drive chronic hepatitis B infection, doing so without changing the underlying DNA sequence.

Tune Therapeutics reported early evidence that the approach can reduce markers of the virus in preclinical studies, suggesting it may interrupt the disease process.

If the findings translate to humans, the method could provide a novel therapeutic option for the millions of patients living with chronic HBV, a condition that currently lacks a definitive cure.

The research was highlighted in a recent R&DCell/Gene Tx report and adds to growing interest in epigenetic strategies for infectious disease treatment.